Hemab Therapeutics (COAG) is a Healthcare company in the Biotechnology industry. It has a market capitalization of $2.29B and a free-cash-flow yield of -4.6%. Nama's AI scorecard rates it Sell, 3.5 out of 10.
AI scorecard
Sell · 3.5/10
Negative, at the mild end of Sell. As of Nov 7, 2026.
Shariah screen
Can't Tell
A figure the screen needs is missing, so it can't tell.
Off its high
-11.6%
How far the last close sits under the highest price of the past five years.
Market cap
$2.29B
Trailing P/E
—
Price / book
5.0
Price / sales
—
FCF yield
-4.6%
Dividend yield
—
Gross margin
0.0%
Operating margin
0.0%
Net margin
0.0%
Revenue growth (YoY)
—
Revenue growth (3-yr annual)
—
EPS growth (YoY)
—
FCF/share growth (YoY)
—
Beta
—
Exchange
NASDAQ
Sector
Healthcare
Industry
Biotechnology
COAG earnings
Next report: Nov 16, 2026 (Q3 2026, EPS estimate -$0.52).
Beat the EPS estimate in 1 of 1 recent quarters.
Quarter
Reported
EPS
Estimate
Surprise
Revenue
Q2 2026
Aug 11, 2026
-$0.80
-$0.82
+2.4%
$0
COAG analyst price target
Median target $62.00 from 6 analysts, ranging $58.00 – $70.00.
Nama's AI scorecard currently rates Hemab Therapeutics Sell (3.5 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.
When does COAG report earnings?
Hemab Therapeutics's next scheduled report is on Nov 16, 2026. Analysts expect EPS of -$0.52.
What is the COAG price target?
The median analyst price target from 6 analysts is $62.00, with a range of $58.00 – $70.00.
Is COAG Shariah compliant?
Nama's AAOIFI-style screen reads Hemab Therapeutics as Can't Tell. A figure the screen needs is missing, so it can't tell.